Caribou Biosciences, Inc. (CRBU)
NASDAQ: CRBU · Real-Time Price · USD
1.870
0.00 (0.00%)
At close: Nov 25, 2025, 4:00 PM EST
1.879
+0.009 (0.49%)
After-hours: Nov 25, 2025, 5:40 PM EST
Caribou Biosciences Revenue
Caribou Biosciences had revenue of $2.20M in the quarter ending September 30, 2025, with 8.60% growth. This brings the company's revenue in the last twelve months to $9.30M, down -19.00% year-over-year. In the year 2024, Caribou Biosciences had annual revenue of $9.99M, down -71.01%.
Revenue (ttm)
$9.30M
Revenue Growth
-19.00%
P/S Ratio
18.62
Revenue / Employee
$63,231
Employees
147
Market Cap
174.79M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.99M | -24.48M | -71.01% |
| Dec 31, 2023 | 34.48M | 20.63M | 148.91% |
| Dec 31, 2022 | 13.85M | 4.25M | 44.31% |
| Dec 31, 2021 | 9.60M | -2.76M | -22.35% |
| Dec 31, 2020 | 12.36M | 6.57M | 113.56% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CRBU News
- 13 days ago - Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 22 days ago - Caribou Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 22 days ago - Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today> - Benzinga
- 22 days ago - Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma - GlobeNewsWire
- 22 days ago - Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies - GlobeNewsWire
- 23 days ago - Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma - GlobeNewsWire
- 3 months ago - Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference - GlobeNewsWire
- 3 months ago - Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire